Chief Medical Officer (CMO) のCampbell Rogers MD. PhDが最新の臨床研究や冠動脈疾患診断検査のトレンドをご紹介します。
The randomized PRECISE trial allows us to more clearly understand the impact of adopting the 2021 Chest Pain Guidelines into daily practice.
“What is now proved was once only imagined.” – Charles Darwin Having recently celebrated its 75th birthday, England’s National Health Service (NHS) has been a
“It is not the strongest of the species that survives, nor the most intelligent. It is the one that is most adaptable to change.”
All truths are easy to understand once they are discovered; the point is to discover them. – Galileo Galilei Discovery drives clinical research. Whether we
The ADVANCE-DK study reminds us that what we think we understand may still be a work in progress.
“What is now proved was once only imagined.” – Charles Darwin Having recently celebrated its 75th birthday, England’s National Health Service (NHS) has been a
“It is not the strongest of the species that survives, nor the most intelligent. It is the one that is most adaptable to change.”
All truths are easy to understand once they are discovered; the point is to discover them. – Galileo Galilei Discovery drives clinical research. Whether we
The ADVANCE-DK study reminds us that what we think we understand may still be a work in progress.
Do my clinical habits put patients at risk? A recent NEJM publication brings this question to the forefront.
Is now the moment when we begin to improve the prevention of advanced CAD faster than its treatment?
ハートフロー・ジャパン合同会社
〒105-6031
東京都港区虎ノ門4丁目3番1号
城山トラストタワー31階
TEL: 03-6809-2521
FAX: 03-6809-2522
FFRCT 分析、RoadMapTM 分析、プラーク分析、ハートフロー プランナーを備えたハートフロー分析は、米国で FDA の認可を受けています。 FFRCT 分析とハートフロー プランナーは、ヨーロッパと英国で CE マークを取 得しており、日本とカナダでも承認されています
FFRCT 分析、RoadMapTM 分析、プラーク分析、およびハートフロー プランナーを備えたハートフロー分析は、米国で市販されています。 FFRCT 分析とハートフロー プランナーは英国で市販されています。 FFRCT 分析は、 ヨーロッパ、日本、カナダでも市販されています。
ハートフロー分析によって提供される情報は、患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。ハートフロー分析はすべての患者に適しているわけ
ではありません。詳細については、それぞれの使用上の注意を参照してください
© 2023 HeartFlow, Inc. | HeartFlowやHeartFlowのロゴ、CT-FlowやCT-FlowのロゴはHeartFlow,Incの商標です。
www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041
*Required fields
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
*Required fields
オンライン提出フォームから研究助成金を申請してください。
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.
If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.Please apply for research grants through our online submission form.
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.
本情報は日本国内の医療関係者を対象とした情報提供サイトです。
一般の方に対する情報提供を目的としたものではございません。
あなたは医療関係者ですか？
